On 14 April 2020, brain disease-focused drug discovery company Cerevance announced it had closed a $45m Series B financing round.
The funding was led by three high-profile new investors: GV (formerly Google Ventures), Microsoft co-founder Bill Gates and Foresight Capital.
Cerevance also received new financing from existing investors: Takeda Ventures – the venture arm of the Japanese pharma giant – as well as the Dementia Discovery Fund and Lightstone Ventures.
The company is planning to use this latest influx of capital to support the clinical development of its lead product in Parkinson’s disease, as well advance four other central nervous system (CNS) candidates into trials.
Read more on pharmaceutical-technology.com